SOJOURNIX
Sojournix, Inc. is a biotechnology company developing innovative medicines for women's health and endocrine disorders.
SOJOURNIX
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
Arlington, Massachusetts, United States
Country:
United States
Website Url:
http://www.sojournixpharma.com
Total Employee:
11+
Status:
Closed
Contact:
(781) 795-4700
Email Addresses:
[email protected]
Total Funding:
70 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud COVID-19 OpenResty
Similar Organizations
Fauna Bio
Fauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Vascugen
Vascugen is a biotechnology company developing regenerative medicine for treatment of intractable vascular diseases.
Current Employees Featured
Founder
Investors List
Boxer Capital
Boxer Capital investment in Series C - Sojournix
Janus Henderson Investors
Janus Henderson Investors investment in Series C - Sojournix
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series C - Sojournix
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series C - Sojournix
RA Capital Management
RA Capital Management investment in Series C - Sojournix
Official Site Inspections
http://www.sojournixpharma.com
Unable to get host informations!!!
More informations about "Sojournix" on Search Engine
Sojournix - Crunchbase Company Profile & Funding
Details. Industries. Biotechnology. Health Care. Medical. Headquarters Regions Greater Boston Area, East Coast, New England. Founded Date 2016. Founders Daniel Grau. …See details»
Sojournix Company Profile - Craft
Nov 5, 2019 See insights on Sojournix including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Sojournix Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Sojournix. Use the PitchBook Platform to explore the full profile.See details»
sojournix - pre-IPO Pharma
Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and …See details»
Sojournix | VentureRadar
Location: USA. Founded in 2016. Private Company. Develops novel neurokinin-3 antagonist medicines to improve women's health and neuroendocrine disorders, offering safe, non …See details»
Sojournix Advances Phase 2 Clinical Trial of SJX‑653
Dec 8, 2020 WALTHAM, Mass.-- ( BUSINESS WIRE )-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health …See details»
Daniel Grau - President, Chief Executive Officer, and Director ...
Primary Organization. Sojournix. Location Arlington, Massachusetts, United States. Regions Greater Boston Area, East Coast, New England. Gender Male. LinkedIn View …See details»
Sojournix Announces Publication of Results from SJX-653 Proof …
Sep 21, 2020 WALTHAM, Mass.-- ( BUSINESS WIRE )-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health …See details»
Sojournix - Funding, Financials, Valuation & Investors - Crunchbase
Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders.See details»
Sojournix Completes $44 Million Series C Financing - PR Newswire
WALTHAM, Mass., Jan. 3, 2019 /PRNewswire/ -- Sojournix, a clinical stage pharmaceutical company focused on creating new medicines to transform the treatment of women's …See details»
Sojournix Announces Positive Top-Line Phase 1 Data …
WALTHAM, Mass., Feb. 13, 2019 /PRNewswire/ -- Sojournix, a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies …See details»
Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX …
Feb 24, 2020 WALTHAM, Mass.-- ( BUSINESS WIRE )-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health …See details»
Sojournix Announces Initiation of Phase 2 Clinical ... - pipelinereview
WALTHAM, MA, USA I February 24, 2020 I Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine …See details»
Sojournix Presents Data at NAMS Showing SJX-653
Sep 28, 2020 Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of …See details»
Sojournix Completes $44M Series C Financing - FinSMEs
Published on January 3, 2019. Sojournix, a Waltham, Mass.-based clinical stage pharmaceutical company focused on creating new medicines for the treatment of …See details»
Sojournix Announces Publication of Results from SJX-653 Proof …
Sep 21, 2020 WALTHAM, Mass.--(BUSINESS WIRE)--Sep 21, 2020-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for …See details»
Sojournix - Contacts, Employees, Board Members, Advisors
Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders.See details»
SOJOURNIX INC | CipherBio
Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders. Stage: Public. Total Funds Raised: $0.00. Funding Products …See details»
Sojournix Announces Initiation of Phase 2 Clinical Trial of
Feb 24, 2020 WALTHAM, Mass.-- ( BUSINESS WIRE )-- Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health …See details»
FDA approves first-in-class NK3 receptor antagonist for hot flushes
May 19, 2023 Asher Mullard. The FDA has approved Astellas’s fezolinetant for moderate to severe hot flushes in menopause. The small molecule is the first neurokinin 3 receptor …See details»